A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era Journal Article
| Authors: | Hosein, P. J.; Maragulia, J. C.; Salzberg, M. P.; Press, O. W.; Habermann, T. M.; Vose, J. M.; Bast, M.; Advani, R. H.; Tibshirani, R.; Evens, A. M.; Islam, N.; Leonard, J. P.; Martin, P.; Zelenetz, A. D.; Lossos, I. S. |
| Article Title: | A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era |
| Abstract: | Summary: Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare subtype of non-Hodgkin lymphoma (NHL) with limited data on pathology and outcome. A multicentre retrospective study was undertaken to determine prognostic factors and the incidence of central nervous system (CNS) relapses. Data was retrospectively collected on patients from 8 US academic centres. Only patients with stage I/II disease (involvement of breast and localized lymph nodes) were included. Histologies apart from primary DLBCL were excluded. Between 1992 and 2012, 76 patients met the eligibility criteria. Most patients (86%) received chemotherapy, and 69% received immunochemotherapy with rituximab; 65% received radiation therapy and 9% received prophylactic CNS chemotherapy. After a median follow-up of 4·5 years (range 0·6-20·6 years), the Kaplan-Meier estimated median progression-free survival was 10·4 years (95% confidence interval [CI] 5·8-14·9 years), and the median overall survival was 14·6 years (95% CI 10·2-19 years). Twelve patients (16%) had CNS relapse. A low stage-modified International Prognostic Index (IPI) was associated with longer overall survival. Rituximab use was not associated with a survival advantage. Primary breast DLBCL has a high rate of CNS relapse. The stage-modified IPI score is associated with survival. © 2014 John Wiley & Sons Ltd. |
| Keywords: | rituximab; breast; central nervous system; lymphoma; diffuse large b-cell lymphoma |
| Journal Title: | British Journal of Haematology |
| Volume: | 165 |
| Issue: | 3 |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2014-05-01 |
| Start Page: | 358 |
| End Page: | 363 |
| Language: | English |
| DOI: | 10.1111/bjh.12753 |
| PROVIDER: | scopus |
| PMCID: | PMC3990235 |
| PUBMED: | 24467658 |
| DOI/URL: | |
| Notes: | Export Date: 1 May 2014 -- CODEN: BJHEA -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work